Biosimilar for Crohn ' s Noninferior to Adalimumab Biosimilar for Crohn ' s Noninferior to Adalimumab
A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news
More News: Crohn's Disease | Food and Drug Administration (FDA) | Gastroenterology | Health | Humira | Inflammatory Bowel Disease | Marketing